Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Receivables: 2011-2024

Historic Receivables for Niagen Bioscience (NAGE) over the last 12 years, with Dec 2024 value amounting to $7.8 million.

  • Niagen Bioscience's Receivables rose 19.87% to $8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.1 million, marking a year-over-year increase of 23.63%. This contributed to the annual value of $7.8 million for FY2024, which is 48.41% up from last year.
  • Niagen Bioscience's Receivables amounted to $7.8 million in FY2024, which was up 48.41% from $5.2 million recorded in FY2023.
  • Niagen Bioscience's 5-year Receivables high stood at $11.6 million for FY2022, and its period low was $3.6 million during FY2020.
  • Its 3-year average for Receivables is $8.2 million, with a median of $7.8 million in 2024.
  • Its Receivables has fluctuated over the past 5 years, first surged by 103.84% in 2021, then plummeted by 54.81% in 2023.
  • Over the past 5 years, Niagen Bioscience's Receivables (Yearly) stood at $3.6 million in 2020, then spiked by 103.84% to $7.3 million in 2021, then soared by 58.09% to $11.6 million in 2022, then crashed by 54.81% to $5.2 million in 2023, then soared by 48.41% to $7.8 million in 2024.